Zhang Ting, Yang Xinrui, Xu Wanping, Wang Jing, Wu Dawei, Hong Zhixian, Yuan Shengxian, Zeng Zhen, Jia Xiaodong, Lu Shanshan, Safadi Rifaat, Han Sen, Yang Zhihong, Neckers Leonard M, Liangpunsakul Suthat, Zhou Weiping, Lu Yinying
Department of the Fifth Medical Center, General Hospital of PLA, Beijing 100039, China.
Division of Gastroenterology and Hepatology, Department of Medicine, Indiana University School of Medicine, Indianapolis 46202, USA.
Cancer Biol Med. 2021 Mar 25;18(3):693-704. doi: 10.20892/j.issn.2095-3941.2020.0262.
Hepatocellular carcinoma (HCC), the main type of liver cancer, has a high morbidity and mortality, and a poor prognosis. RNA helicase DDX5, which acts as a transcriptional co-regulator, is overexpressed in most malignant tumors and promotes cancer cell growth. Heat shock protein 90 (HSP90) is an important molecular chaperone in the conformational maturation and stabilization of numerous proteins involved in cell growth or survival.
DDX5 mRNA and protein expression in surgically resected HCC tissues from 24 Asian patients were detected by quantitative real-time PCR and Western blot, respectively. The interaction of DDX5-HSP90 was determined by molecular docking, immunoprecipitation, and laser scanning confocal microscopy. The autophagy signal was detected by Western blot. The cell functions and signaling pathways of DDX5 were determined in 2 HCC cell lines. Two different murine HCC xenograft models were used to determine the function of DDX5 and the therapeutic effect of an HSP90 inhibitor.
HSP90 interacted directly with DDX5 and inhibited DDX5 protein degradation in the AMPK/ULK1-regulated autophagy pathway. The subsequent accumulation of DDX5 protein induced the malignant phenotype of HCC by activating the β-catenin signaling pathway. The silencing of DDX5 or treatment with HSP90 inhibitor both blocked tumor growth in a murine HCC xenograft model. High levels of HSP90 and DDX5 protein were associated with poor prognoses.
HSP90 interacted with DDX5 protein and subsequently protected DDX5 protein from AMPK/ULK1-regulated autophagic degradation. DDX5 and HSP90 are therefore potential therapeutic targets for HCC.
肝细胞癌(HCC)是肝癌的主要类型,发病率和死亡率高,预后差。RNA解旋酶DDX5作为转录共调节因子,在大多数恶性肿瘤中过表达并促进癌细胞生长。热休克蛋白90(HSP90)是一种重要的分子伴侣,参与细胞生长或存活相关众多蛋白质的构象成熟和稳定。
分别采用定量实时PCR和蛋白质免疫印迹法检测24例亚洲患者手术切除的HCC组织中DDX5 mRNA和蛋白表达。通过分子对接、免疫沉淀和激光扫描共聚焦显微镜确定DDX5与HSP90的相互作用。采用蛋白质免疫印迹法检测自噬信号。在2种HCC细胞系中确定DDX5的细胞功能和信号通路。使用2种不同的小鼠HCC异种移植模型确定DDX5的功能及HSP90抑制剂的治疗效果。
HSP90直接与DDX5相互作用,并在AMPK/ULK1调节的自噬途径中抑制DDX5蛋白降解。随后DDX5蛋白的积累通过激活β-连环蛋白信号通路诱导HCC的恶性表型。在小鼠HCC异种移植模型中,DDX5沉默或用HSP90抑制剂处理均能阻断肿瘤生长。HSP90和DDX5蛋白水平高与预后不良相关。
HSP90与DDX5蛋白相互作用,随后保护DDX5蛋白免受AMPK/ULK1调节的自噬降解。因此,DDX5和HSP90是HCC潜在的治疗靶点。